Deutsche Bank Adjusts Spyre Therapeutics Price Target to $141 From $123, Maintains Buy Rating
Deutsche Bank has increased its price target for Spyre Therapeutics, Inc. while maintaining a Buy rating on the stock.
Stocks · News reference
Spyre Therapeutics announced that its management team will participate in several investor conferences throughout November and December 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Deutsche Bank has increased its price target for Spyre Therapeutics, Inc. while maintaining a Buy rating on the stock.
Spyre Therapeutics, Inc. announced that its management team will participate in the UBS Global Biopharma Conference in London on November 16, 2026.
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
Spyre Therapeutics' independent Compensation Committee approved the grant of stock options and restricted stock units to new employees.
Deutsche Bank has revised its price target for Spyre Therapeutics, lowering it from $127 to $123.
Wedbush Securities reaffirmed its 'Outperform' rating on Spyre Therapeutics while adjusting the price target to $120 from $123.